RIVASTIGMINE Tartrate Capsules, USP, 1.5 mg, 60-count bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachupally 500-900 India, NDC 55111-352-60
Published April 12, 2017 · Recall initiated: March 6, 2017
Summary
FDA records drug Class III recall D-0649-2017, published April 12, 2017 and initiated March 6, 2017. Recalling firm: Dr. Reddy's Laboratories, Inc.; Status: Terminated; Reported quantity: 1,728 bottles; Lot: Lot #C607323, Exp 10/18. Class III means the product is not likely to cause adverse health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine.
What to do
Voluntary: Firm initiated · Letter
Get an email if RIVASTIGMINE TARTRATE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- RIVASTIGMINE TARTRATE
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Distributor
- U.S. nationwide
- Lot
- Lot #C607323, Exp 10/18
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDACotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by GenentechApril 12, 2017
- FDAQuinapril Tablets USP 5 mg, 90 count bottles, Lupin Pharmaceuticals, Inc., Baltimore, MD --- NDC 68180-556-09April 12, 2017
- FDAFluphenazine Decanoate Injection, USP; 25 mg/mL, 5mL vials, Rx only, APP Pharmaceuticals, LLC Schaumburg, ILApril 12, 2017
- FDARegeneSlimApril 12, 2017
- FDAXtraHRD Natural Male Enhancement Capsules, Herbal Dietary Supplement, 500 mg capsules, 2, 4 and 10 countApril 12, 2017
- FDARegeneArouseApril 12, 2017
Questions about this recall
Was RIVASTIGMINE Tartrate Capsules, USP, 1.5 mg, 60-count bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachupally 500-900 India, NDC 55111-352-60 recalled?
Yes. FDA published recall D-0649-2017 on April 12, 2017. Reported hazard: Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: RIVASTIGMINE TARTRATE.